Compare Stocks → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ASLNNASDAQ:CBIONASDAQ:EPIXNASDAQ:TRVNNASDAQ:VRNA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASLNASLAN Pharmaceuticals$0.49$0.61$0.39▼$4.69$8.03M1.45876,959 shs152,904 shsCBIOCatalyst Biosciences$0.77$0.19▼$8.69$291.29M1.05763,526 shs32,246 shsEPIXESSA Pharma$7.07-4.8%$8.82$2.56▼$11.67$312.78M1.62139,916 shs26,743 shsTRVNTrevena$0.40+2.6%$0.52$0.30▼$3.28$7.30M1.1159,736 shs3.52 million shsVRNAVerona Pharma$16.40+1.2%$16.53$11.83▼$23.81$1.33B0.4498,326 shs348,625 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASLNASLAN Pharmaceuticals-2.69%-13.74%-24.35%-6.33%-86.45%CBIOCatalyst Biosciences0.00%0.00%0.00%0.00%+3,234.57%EPIXESSA Pharma+1.78%-3.88%-17.44%-11.65%+163.48%TRVNTrevena+0.41%-1.82%-28.55%-42.63%-47.61%VRNAVerona Pharma+2.53%-1.64%+3.51%-6.03%-24.41%Could Bitcoin Literally FORCE This Crypto To Rocket Up? (Ad)Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASLNASLAN Pharmaceuticals2.6118 of 5 stars3.55.00.00.02.30.80.6CBIOCatalyst BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AEPIXESSA Pharma2.8238 of 5 stars3.54.00.00.02.73.30.0TRVNTrevena1.2969 of 5 stars3.53.00.00.01.40.00.6VRNAVerona Pharma1.3061 of 5 stars3.50.00.00.02.81.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASLNASLAN Pharmaceuticals3.00Buy$11.332,208.21% UpsideCBIOCatalyst BiosciencesN/AN/AN/AN/AEPIXESSA Pharma3.00Buy$16.50133.38% UpsideTRVNTrevena3.00Buy$9.002,160.17% UpsideVRNAVerona Pharma3.00Buy$33.60104.88% UpsideCurrent Analyst RatingsLatest EPIX, TRVN, CBIO, ASLN, and VRNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024VRNAVerona PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$31.00 ➝ $36.004/15/2024ASLNASLAN PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.004/2/2024TRVNTrevenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/18/2024ASLNASLAN PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $9.003/13/2024ASLNASLAN PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$15.00 ➝ $10.003/4/2024VRNAVerona PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.003/1/2024VRNAVerona PharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$33.001/22/2024VRNAVerona PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00(Data available from 4/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASLNASLAN Pharmaceuticals$12M0.67N/AN/A$0.60 per share0.82CBIOCatalyst Biosciences$790K0.00N/AN/A($0.78) per share0.00EPIXESSA PharmaN/AN/AN/AN/A$3.30 per shareN/ATRVNTrevena$3.12M2.34N/AN/A($0.44) per share-0.91VRNAVerona Pharma$460K2,881.41N/AN/A$3.10 per share5.29Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASLNASLAN Pharmaceuticals-$44.22M-$2.74N/A∞N/AN/A-862.59%-82.83%4/26/2024 (Estimated)CBIOCatalyst Biosciences-$8.24M-$1.38N/AN/AN/AN/A-364.68%-281.68%N/AEPIXESSA Pharma-$26.58M-$0.59N/AN/AN/AN/A-17.41%-17.04%5/14/2024 (Estimated)TRVNTrevena-$40.29M-$3.13N/AN/AN/AN/A-1,018.15%-98.93%5/20/2024 (Estimated)VRNAVerona Pharma-$54.37M-$0.69N/AN/AN/AN/A-20.47%-17.72%5/14/2024 (Estimated)Latest EPIX, TRVN, CBIO, ASLN, and VRNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/29/2024Q4 2023VRNAVerona Pharma-$0.23-$0.16+$0.07-$0.16N/AN/A2/13/202412/31/2023EPIXESSA Pharma-$0.17-$0.14+$0.03-$0.14N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASLNASLAN PharmaceuticalsN/AN/AN/AN/AN/ACBIOCatalyst BiosciencesN/AN/AN/AN/AN/AEPIXESSA PharmaN/AN/AN/AN/AN/ATRVNTrevenaN/AN/AN/AN/AN/AVRNAVerona PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASLNASLAN PharmaceuticalsN/A2.112.11CBIOCatalyst BiosciencesN/A2.882.88EPIXESSA PharmaN/A40.7440.74TRVNTrevena8.354.664.66VRNAVerona Pharma0.2033.3333.33OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASLNASLAN Pharmaceuticals58.82%CBIOCatalyst Biosciences5.98%EPIXESSA Pharma75.12%TRVNTrevena13.56%VRNAVerona Pharma85.88%Insider OwnershipCompanyInsider OwnershipASLNASLAN Pharmaceuticals4.69%CBIOCatalyst Biosciences2.92%EPIXESSA Pharma14.70%TRVNTrevena2.40%VRNAVerona Pharma4.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableASLNASLAN Pharmaceuticals3416.35 million15.58 millionOptionableCBIOCatalyst Biosciences737.98 million36.87 millionOptionableEPIXESSA Pharma5044.24 million37.74 millionOptionableTRVNTrevena2318.32 million17.88 millionOptionableVRNAVerona Pharma7980.82 million76.94 millionOptionableEPIX, TRVN, CBIO, ASLN, and VRNA HeadlinesSourceHeadlineVerona Pharma (NASDAQ:VRNA) Price Target Increased to $36.00 by Analysts at Piper Sandleramericanbankingnews.com - April 17 at 3:36 AMVerona Pharma (NASDAQ:VRNA) Trading 3.7% Higher After Analyst Upgradeamericanbankingnews.com - April 17 at 1:08 AMVerona Pharma (NASDAQ:VRNA) Stock Price Up 3.7% on Analyst Upgrademarketbeat.com - April 16 at 10:36 AMVerona Pharma (NASDAQ:VRNA) PT Raised to $36.00 at Piper Sandlermarketbeat.com - April 16 at 8:33 AMVerona Pharma (NASDAQ:VRNA) Shares Up 4.9%marketbeat.com - April 4 at 3:08 PMAmerican Century Companies Inc. Purchases Shares of 280,126 Verona Pharma plc (NASDAQ:VRNA)marketbeat.com - March 28 at 4:07 AMWellington Management Group LLP Acquires 164,268 Shares of Verona Pharma plc (NASDAQ:VRNA)marketbeat.com - March 19 at 4:54 AMVRNA Apr 2024 17.500 callfinance.yahoo.com - March 16 at 8:32 AMVRNA Apr 2024 15.000 callfinance.yahoo.com - March 16 at 3:31 AMAndrew Fisher Joins Verona Pharma as General Counselglobenewswire.com - March 4 at 2:00 AMBuy Rating Affirmed: Verona Pharma’s Promising Future with Ensifentrine and Expanding R&D Pipelinemarkets.businessinsider.com - March 1 at 1:10 PMVerona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 1 at 1:10 PM3 Healthcare Stocks That Have Outperformed Nvidia Since 2022fool.com - March 1 at 8:45 AMVerona Pharma plc 2023 Q4 - Results - Earnings Call Presentationseekingalpha.com - February 29 at 11:18 AMVerona Pharma plc: Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - February 29 at 10:48 AMVerona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Resultsfinance.yahoo.com - February 29 at 10:48 AMVerona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updateglobenewswire.com - February 29 at 2:00 AMVerona Pharma earnings preview: what to expectmarkets.businessinsider.com - February 28 at 1:35 PMWhen Will Verona Pharma plc (NASDAQ:VRNA) Turn A Profit?finance.yahoo.com - February 25 at 12:52 PMVerona Pharma PLC ADRwsj.com - February 25 at 7:52 AMVRNA Mar 2024 15.000 putfinance.yahoo.com - February 17 at 7:46 PMVRNA Jun 2024 30.000 callfinance.yahoo.com - February 17 at 2:46 PMVerona Pharma: A Few Points From The Bull And Bear Caseseekingalpha.com - February 15 at 5:55 PMVerona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Updatefinance.yahoo.com - February 15 at 10:20 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsASLAN PharmaceuticalsNASDAQ:ASLNASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.Catalyst BiosciencesNASDAQ:CBIOCatalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.ESSA PharmaNASDAQ:EPIXESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.TrevenaNASDAQ:TRVNTrevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.Verona PharmaNASDAQ:VRNAVerona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.